Drugs / AAHI-SC3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05370040 | May 2022 → Mar 2024 | COVID-19 | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAHI-SC3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370040 ↗ |
| Modality | Small activating RNA (saRNA) | “AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine” NCT05370040 ↗ |
| Route | Intramuscular | “AAHI-SC3 on Day 1 at dosage 25 μg IM” NCT05370040 ↗ |